—
Summary‘Friedreich Ataxia - Pipeline Review, H2 2016’, provides an overview of the Friedreich Ataxia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/693296-friedreich-ataxia-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Friedreich Ataxia
- The report reviews pipeline therapeutics for Friedreich Ataxia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Friedreich Ataxia therapeutics and enlists all their major and minor projects
- The report assesses Friedreich Ataxia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Friedreich Ataxia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Friedreich Ataxia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Friedreich Ataxia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693296-friedreich-ataxia-pipeline-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Friedreich Ataxia Overview 9
Therapeutics Development 10
Pipeline Products for Friedreich Ataxia - Overview 10
Pipeline Products for Friedreich Ataxia - Comparative Analysis 11
Friedreich Ataxia - Therapeutics under Development by Companies 12
Friedreich Ataxia - Therapeutics under Investigation by Universities/Institutes 14
Friedreich Ataxia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Friedreich Ataxia - Products under Development by Companies 18
Friedreich Ataxia - Products under Investigation by Universities/Institutes 19
Friedreich Ataxia - Companies Involved in Therapeutics Development 20
Adverum Biotechnologies, Inc. 20
Almirall, S.A. 21
BioMarin Pharmaceutical Inc. 22
Biovista Inc. 23
Catabasis Pharmaceuticals, Inc. 24
Edison Pharmaceuticals, Inc. 25
Horizon Pharma Plc 26
Ixchel Pharma, LLC 27
ProQR Therapeutics N.V. 28
RaNA Therapeutics, Inc. 29
Reata Pharmaceuticals, Inc. 30
Retrotope, Inc 31
Shire Plc 32
STATegics, Inc. 33
Voyager Therapeutics, Inc. 34
Friedreich Ataxia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
AGIL-FA - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ANN-003 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
BVA-202 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BVA-203 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CAT-4001 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
dimethyl fumarate - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Gene Therapy to Activate Frataxin for Friedreich’s Ataxia - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Gene Therapy to Activate Frataxin for Friedreich’s Ataxia - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
interferon gamma-1b - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
interferon gamma-1b - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
IXC-101 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
JOT-101 - Drug Profile 60
Product Description 60
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693296
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140101
Google
RSS